Clinical trial

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

NCT02389933

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2021-02-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Heart Failure With Reduced Ejection Fraction (HF-rEF)unresolved

Interventions

LCZ696DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

AthensGreece13 MadridSpain4 FrankfurtGermany4 ParisFrance3 MarseilleFrance3 LyonFrance3 DresdenGermany3 CologneGermany3 ThessalonikiGreece3 BerlinGermany2 ToulouseFrance2 SevilleSpain2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02389933 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.